For research use only
| Cat No. | ABC-TC0279 |
| Product Type | Human Lymphoma Cell Lines |
| Cell Type | Lymphoblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | CVCL_2461 |
Human lymphoma. Derivative of the Jurkat cell line and secretes Interleukin 2. The cells should be handled under laboratory containment level 2.
H33HJ-JA1 is a human lymphoblastic cell line derived from the peripheral blood of a patient with precursor T-cell acute lymphoblastic leukemia (T-ALL) and is a derivative of the Jurkat cell line that secretes Interleukin 2 (IL-2). This cell line exhibits typical lymphoblast-like morphology and grows in suspension culture. Although the detailed karyotype of H33HJ-JA1 has not been independently published, it is expected to harbor chromosomal abnormalities commonly observed in T-ALL-derived cell lines (e.g., aneuploidy, structural rearrangements). H33HJ-JA1 has not been reported to exhibit tumorigenic or metastatic potential in vivo, but it serves as a valuable in vitro model for studying T-cell activation, apoptosis regulation, and immune signaling pathways. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | CVCL_2461 |
| Species | Human |
| Cat.No | ABC-TC0279 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
H33HJ-JA1 cells are suitable for in vitro drug screening, gene expression analysis, and biomarker discovery. Their reproducible growth and response characteristics make them valuable for modeling relevant biological processes related to T-cell-associated diseases and evaluating the efficacy of new therapeutic agents targeting T-cell-related disorders in preclinical research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
